Navigation Links
Chembio Reports 3rd Quarter 2011 Results
Date:11/3/2011

n increased by $2.08 million, or 71.6% ($4.99 million vs. $2.91 million), as compared with the comparable period in 2010.
  • Research and development expenses increased by $.87 million, or 31%, to $3.70 million compared to $2.82 million in the 2010 period.  The increase is primarily due to an increase of $.66 million in clinical trial expenses.
  • Selling General & Administrative Expenses increased by $.27 million or 12.6% in the first nine months of 2011 as compared to the first nine months of 2010.  This was primarily due to an increase in commissions for the shipment of our DPP® products to Brazil.
  • Operating income was approximately $.54 million in the first nine months of 2011 as compared to operating income in the first nine months of 2010 of $.64 million. In addition, net income was approximately $.53 million in the first nine months of 2011 as compared to net income in the first nine months of 2010 of $.63 million.
  • The September 30, 2011 cash balance was $3.05 million as compared with $2.14 million at  December 31,  2010.  The increase in the 2011 period includes cash received from the change in receivables of $1.29 million, an increase in deferred revenue of $426,000, an increase of $289,000 in loans from HSBC on the revolver for equipment purchases and a $290,000 increase in accounts payable partially offset by an increase in inventories of $1.24 million.  In addition the Company received $205,000 from the exercise of warrants.  The increased cash from operations in 2011 was also attributable to non-cash expenses aggregating $458,000, primarily from depreciation and amortization expense.

  • Summary of Clinical, Development and Regulatory ActivitiesCLINICAL & REGULATORYCE Mark for FDA approved HIV tests -- The final studies for the CE Marking requirements are complete and we submitted this data during October 2011.  

    Regulatory Approvals in Brazil throu
    '/>"/>

    SOURCE Chembio Diagnostics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related medicine technology :

    1. Chembio to Host Conference Call to Discuss 3rd Quarter 2011 Financial Results
    2. Chembio Diagnostics CFO Richard J. Larkin Among the Recipients of "2011 CFO of the Year" Award from Long Island Business News
    3. NxStage Reports Record Third Quarter 2011 Financial Results and Raises Revenue Guidance For 2011
    4. Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results
    5. CVS Caremark Reports Third Quarter Results
    6. Onyx Pharmaceuticals Reports Third Quarter 2011 Financial Results
    7. Idenix Pharmaceuticals Reports Third Quarter and Nine Month 2011 Financial Results and Provides Pipeline Update
    8. Nektar Therapeutics Reports Third Quarter 2011 Financial Results
    9. Par Pharmaceutical Companies Reports Third Quarter 2011 Results
    10. Luminex Corporation Reports Third Quarter 2011 Results
    11. Anthera Pharmaceuticals Reports 2011 Third Quarter Financial Results and Operational Update
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... DALLAS , Jan. 15, 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com ... to its store . (Photo: ... consumption upgrade and policy support, China,s ... the years, with total market size rising from 3.28 ...
    (Date:1/15/2014)... AARP Foundation today announced it has established a relief ... cold weather that has gripped much of the nation. AARP ... so to support these emergency relief efforts AARP and AARP ... mean up to $500,000 in aid. The matching program will ...
    (Date:1/15/2014)... plc (LSE: SHP, NASDAQ: SHPG ) announces that it ... the announced tender offer for all of the outstanding shares of ... the waiver, the transaction is no longer conditional on OFT approval, ... 2014 following the currently scheduled expiration time, subject to the satisfaction ...
    Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
    ... NEW YORK, Oct. 25, 2011 Reportlinker.com ... is available in its catalogue: ... Market Forecasts to 2018 ... - Pipeline Assessment and Market Forecasts to ...
    ... YORK, Oct. 25, 2011 Reportlinker.com ... report is available in its catalogue: ... Market to 2017 - Patent Expiries ... Aricept, Namenda, Avonex, Rebif and Copaxone ...
    Cached Medicine Technology:Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018 2Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018 3Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018 4Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018 5Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018 6Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018 7Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018 8Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018 9Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018 10Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018 11Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018 12Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 2Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 3Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 4Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 5Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 6Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 7Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 8Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 9Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 10Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 11Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 12Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 13Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 14Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 15
    (Date:4/23/2014)... Alzheimer,s disease has been a rapidly evolving pursuit ... latest crook in the research road, scientists have ... proteins associated with the disease. The report, which ... , could have important implications for developing novel ... colleagues explain that for years, research has suggested ...
    (Date:4/22/2014)... the New Jersey Institute of Technology (NJIT) today ... the launch of the New Jersey Innovation Institute ... model for business innovation through the leveraging of ... U.S. Senator Cory Booker, Panasonic Corp. of North ... Lieutenant Governor Kim Guadagno, New Jersey Secretary of ...
    (Date:4/22/2014)... the last few decades researchers have characterized a set ... and behavior in all types of species, from flies ... identified, but researchers surmise there are more. A team ... of Pennsylvania wondered if big-data approaches could find them. ... by John Hogenesch, PhD, professor of Pharmacology and first ...
    (Date:4/22/2014)... Researchers at UT Southwestern Medical Center are making breakthroughs ... , A team of physician-scientists at UT Southwestern ... hormone with natural anti-depressant properties) works inside the brain. ... for depression in the form of a neuroprotective drug ... online in April,s issue of Molecular Psychiatry, ...
    (Date:4/22/2014)... women using a newer method of planned sterilization called ... a 10-year period than using the more commonly performed ... and UC Davis has found. , Published online ... study found the higher risk of pregnancy with a ... , "This study provides essential information for women ...
    Breaking Medicine News(10 mins):Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Bioinformatics profiling identifies a new mammalian clock gene 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3Health News:Risk of pregnancy greater with newer method of female sterilization 2Health News:Risk of pregnancy greater with newer method of female sterilization 3
    ... March issue of Neurology, the epilepsy drug Valproate has been ... ,For pregnant women with epileptic seizures, often the ... who took the drug in their first trimester of pregnancy ... the study was collected from pregnant women in US and ...
    ... has for decades focused on finding the underlying genetic ... genes themselves are controlled by components outside the nucleus ... microenvironment," said researcher Maniotis. ,Research finding at ... malignancy also depends on the molecules that surrounds the ...
    ... adding the drug rasagiline to standard treatment with levodopa ... patients spend suffering from motor fluctuations they experience during ... once-daily oral rasagiline to the drug entacapone, which must ... in around 690 patients. Both of the additional drugs ...
    ... able to monitor their blood sugar around the clock without ... ,A new device that measures blood sugar by testing ... out by a transdermal low-level electric current -- and then ... effective even in children under age 7. ,Studies were ...
    ... to suggest that supplementing the diet with vitamin E ... study published In Journal Of American Medical association, says ... something very different. ,The researchers had studied ... or HOPE centers between 1993 and 1999, and the ...
    ... says that oil from the fishes contains a property that ... Salmon, if are taken in a diet supplemented by low ... disease and arthritis. In case of absence of fish, a ... trick. ,Trials have shown previously that omega-3 fatty acids ...
    Cached Medicine News:Health News:Cell’s microenvironment linked to cancer 2
    ... Merit has a complete offering of ... Performa brands, these catheters are designed with ... shaft strength and better push-ability, and large ... in 4, 5, 6 and 7 French ...
    Used to negotiate tortuous vessels....
    Used for vascular and non-vascular applications. Tapered fixed core construction provides gradual transition to a flexible,tip. Supplied sterile in peel-open packages. Intended for one-time use....
    Used to negotiate tortuous vessels....
    Medicine Products: